Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm
Por:
Montalban, C, Diaz-Lopez, A, Martin, A, Baile, M, Sanchez, JM, Sancho, JM, Garcia, O, Novelli, S, Monter-Rovira, A, Salar, A, Bastos, M, Gutierrez, A, Bento, L, Corboda, R, Arquero, T, de Villambrosia, SG, Barranco, G, De Ona, R, Guillermo, AL, Salazar, MJR, Dominguez, JF, Fernandez, R, Queizan, JA, Rodriguez, J, Abraira, V, Garcia, JF
Publicada:
1 ago 2018
Resumen:
The Grupo Espanol de Linfomas y Trasplantes de Medula Osea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups in diffuse large B cell lymphoma (DLBCL) patients treated with immunochaemotherapy: low (LR), low-intermediate (LIR), high-intermediate (HIR), and high (HR). The present study explores the effect of GELTAMO-IPI in the DLBCL subtypes defined by the immunohistochaemistry-based Hans algorithm, Germinal Centre B (GCB) and non-GCB. A multivariate Cox regression model including GELTAMO-IPI risk groups, cell of origin (COO) subtypes and their product was developed to evaluate interaction between the two variables. The COO subtype was available in 839 patients (380 GCB; 459 non-GCB) and both the GELTAMO-IPI and the COO subtype in 780 (353 GCB; 427 non-GCB). There were no differences in 5-year overall survival (OS) between the two subtypes. The Cox model revealed interaction between the GELTAMO-IPI risk groups and the COO subtypes (P=0.005), indicating that GELTAMO-IPI has a different effect in the two subtypes. Three risk groups were stratified in both COO subtypes: in the GCB subtype, LR, LIR and the combined HIR+HR had 5-year OS of 100%, 75% and 52%, respectively. In the non-GCB subtype, LR, the combined LIR+HIR and HR had a 5-year OS of, 97%, 82% and 35% respectively. GELTAMO-IPI identifies a genuine poor outcome group of patients in the DLBCL non-GCB subtype.
Filiaciones:
Montalban, C:
MD Anderson Canc Ctr, Dept Haematol, Arturo Soria 270, Madrid 28033, Spain
Diaz-Lopez, A:
MD Anderson Canc Ctr, Dept Pathol, Translat Res, Madrid, Spain
Martin, A:
Hosp Univ Salamanca, Dept Haematol, Salamanca, Spain
CIBERONC, IBSAL, Salamanca, Spain
Baile, M:
Hosp Univ Salamanca, Dept Haematol, Salamanca, Spain
CIBERONC, IBSAL, Salamanca, Spain
Sanchez, JM:
Hosp Univ, Dept Haematol, 12 Octubre, Madrid, Spain
Sancho, JM:
Hosp Badalona Germans Trias & Pujol, IJC, ICO, Dept Haematol, Badaiona, Spain
Garcia, O:
Hosp Badalona Germans Trias & Pujol, IJC, ICO, Dept Haematol, Badaiona, Spain
Novelli, S:
Hosp Santa Creu I St Pau, Dept Haematol, Barcelona, Spain
Monter-Rovira, A:
Hosp Santa Creu I St Pau, Dept Haematol, Barcelona, Spain
Salar, A:
Hosp del Mar, Dept Haematol, Barcelona, Spain
Bastos, M:
Hosp Gregorio Maranon, Dept Haematol, Madrid, Spain
Gutierrez, A:
Hosp Univ Son Espases, Dept Haematol, Palma de Mallorca, Spain
Bento, L:
Hosp Univ Son Espases, Dept Haematol, Palma de Mallorca, Spain
Corboda, R:
Fdn Jimenez Diaz, Dept Haematol, Madrid, Spain
Arquero, T:
Fdn Jimenez Diaz, Dept Haematol, Madrid, Spain
de Villambrosia, SG:
Hosp Univ Marque Valdecilla, Dept Haematol, Santander, Spain
Barranco, G:
MD Anderson Canc Ctr, Dept Pathol, Translat Res, Madrid, Spain
De Ona, R:
MD Anderson Canc Ctr, Dept Haematol, Arturo Soria 270, Madrid 28033, Spain
Guillermo, AL:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Salazar, MJR:
Hosp Univ Canarias, Dept Haematol, Santa Cruz De Tenerife, Spain
Dominguez, JF:
Hosp Virgen Rocio, Dept Haematol, Seville, Spain
Fernandez, R:
Hosp Cabuenes, Dept Haematol, Gijon, Spain
Queizan, JA:
Hosp Gen Segovia, Dept Haematol, Segovia, Spain
Rodriguez, J:
MD Anderson Canc Ctr, Dept Haematol, Arturo Soria 270, Madrid 28033, Spain
MD Anderson Canc Ctr, Dept Pathol, Translat Res, Madrid, Spain
Abraira, V:
Hosp Univ Ramon y Cajal, Fdn IRYCIS, Madrid, Spain
Garcia, JF:
MD Anderson Canc Ctr, Dept Pathol, Translat Res, Madrid, Spain
MD Anderson Canc Ctr, Dept Pathol, Madrid, Spain
Bronze
|